Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
Holding ABCL?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.13Last Year’s EPS
-$0.16Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: 2.08%
|Next Earnings Date:Feb 25, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook. While AbCellera demonstrates strong liquidity and pipeline progress, the financials reveal increased losses and flat revenue growth. The transition to a clinical stage biotech and expansion in partnerships are positive, but financial challenges remain.Company Guidance
During AbCellera's Q3 2024 earnings call, key guidance included financial updates and strategic progress. The company reported a strong liquidity position with approximately $670 million in cash and equivalents, alongside $210 million in available government funding, providing a total available liquidity of about $880 million to support its strategic initiatives. AbCellera started work on two partner-initiated programs in the quarter, bringing the cumulative total to 95 programs with downstream participation. Revenue for Q3 2024 was nearly $7 million, similar to the previous year, primarily from research fees. R&D expenses increased to approximately $41 million, reflecting ongoing program execution and internal program pipeline investment. The net loss for the quarter was around $51 million, translating to a loss of $0.17 per share. The company continues to prioritize internal program development and expects to maintain a similar level of operating expenses into 2025, while capital expenditures related to its infrastructure build are projected to decline significantly by then.Strong Liquidity Position
AbCellera has approximately $670 million in cash and equivalents and $210 million in available government funding, totaling $880 million in liquidity to execute their strategy.
Pipeline Progress and Transition to Clinical Stage
The company is on track with the transition to a clinical stage biotech, with ABCL635 and ABCL575 expected for CTA filings in Q2 2025. They are also advancing a broad portfolio of discovery stage programs.
Expansion in Partnerships
AbCellera expanded their partnership with Eli Lilly, focusing on co-development collaborations with co-ownership of resulting assets.
Completion of New Headquarters
The move into the new headquarters in Vancouver was completed, and the GMP manufacturing facility is on track to come online in 2025.
---
ABCL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABCL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $2.89 | $2.72 | -5.88% |
| Aug 06, 2024 | $2.85 | $2.63 | -7.72% |
| May 07, 2024 | $4.04 | $3.84 | -4.95% |
| Feb 20, 2024 | $5.31 | $4.81 | -9.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AbCellera Biologics (ABCL) report earnings?
AbCellera Biologics (ABCL) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is AbCellera Biologics (ABCL) earnings time?
AbCellera Biologics (ABCL) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABCL EPS forecast?
ABCL EPS forecast for the fiscal quarter 2024 (Q4) is -$0.13.
---